Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 20% Improvement Relative Risk Ivermectin  Elavarasi et al.  LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? Retrospective 1,758 patients in India (April - June 2021) Lower mortality with ivermectin (not stat. sig., p=0.12) Elavarasi et al., Lung India, August 2021 Favors ivermectin Favors control

Clinical features, demography, and predictors of outcomes of SARS-CoV-2 infection at a tertiary care hospital in India: A cohort study

Elavarasi et al., Lung India, doi:10.4103/lungindia.lungindia_493_21
Aug 2021  
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective 2017 hospitalized patients in India, showing lower mortality with ivermectin treatment in unadjusted results. No group details are provided and this result is subject to confounding by indication.
This is the 61st of 102 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 560 quintillion).
49 studies are RCTs, which show efficacy with p=0.00000038.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
Study covers ivermectin, zinc, and remdesivir.
risk of death, 19.6% lower, RR 0.80, p = 0.12, treatment 48 of 283 (17.0%), control 311 of 1,475 (21.1%), NNT 24, unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Elavarasi et al., 12 Aug 2021, retrospective, India, peer-reviewed, 31 authors, study period April 2021 - June 2021, dosage not specified.
This PaperIvermectinAll
Clinical features, demography, and predictors of outcomes of SARS-CoV-2 infection at a tertiary care hospital in India: A cohort study
Dr Sushma Bhatnagar, Arunmozhimaran Elavarasi, Harikrishna Raju Sagiraju, Rohitkumar Garg, Brajesh Ratre, Prashant Sirohiya, Nishkarsh Gupta, Rakesh Garg, Anuja Pandit, Saurabh Vig, Ram Singh, Balbir Kumar, Vedprakash Meena, Naveet Wig, Saurabh Mittal, Sourabh Pahuja, Karan Madan, Randeep Guleria, Anant Mohan, Tanima Dwivedi, Ritu Gupta, Ashimajain Vidyarthi, Rama Chaudhry, Arghya Das, Laxmitej Wundavalli, Angelrajan Singh, Sheetal Singh, Sunil Kumar, Manisha Pandey, Abhinav Mishra, Karanvirsingh Matharoo
Lung India, doi:10.4103/lungindia.lungindia_493_21
Background: The "second wave" of the COVID-19 pandemic hit India from early April 2021 to June 2021. We describe the clinical features, treatment trends, and baseline laboratory parameters of a cohort of patients with SARS-CoV-2 infection and their association with the outcome. Methods: This was a retrospective cohort study. Multivariate logistic regression models were fitted to identify clinical and biochemical predictors of developing hypoxia, deterioration during the hospital stay, and death. Results: A total of 2080 patients were included. The case fatality rate was 19.5%. Among the survivors, the median duration of hospital stay was 8 (5-11) days. Out of 853 (42.3%%) of patients who had COVID-19 acute respiratory distress syndrome at presentation, 340 (39.9%) died. Patients aged >45 years had higher odds of death as compared to the 18-44 years age group. Vaccination reduced the odds of death by 40% (odds ratio [OR] [95% confidence interval [CI]]: 0.6 [0.4-0.9], P = 0.032). Patients with hyper inflammation at baseline as suggested by leukocytosis (OR [95% CI]: 2.1 [1.5-3.1], P < 0.001), raised d-dimer >500 mg/dL (OR [95% CI]: 3.2 [2.2-4.7], P < 0.001), and raised C-reactive peptide >0.5 mg/L (OR [95% CI]: 3.7 [2.2-13], P = 0.037) had higher odds of death. Patients who were admitted in the 2 nd week had lower odds and those admitted in the 3 rd week had higher odds of death.
Conflicts of interest There are no conflicts of interest. 1.2 (0.9-1.6), 0.199 1 (0.7-1.5), 0.980 1 (0.6-1.7), 0.943 1.1 (0.7-1.9), 0.708 Primary condition (Reference: COVID) Non-COVID 3.5 (1.7-7.2), 0.001 1.2 (0.4-3.5), 0.705 0.8 (0.3-2•6), 0.729 0.5 (0.1-1.8), 0.266 Mucor 0.5 (0.1-4.0), 0.472 0.9 (0.1-11), 0.940 Vaccinated 0.7 (0.5-1.0), 0.060 0.6 (0.4-0.9), 0.032 0.5 (0.3-0.9), 0.014 0.6 (0.3-0.9), 0.042 Symptom onset to hospitalization (Reference: 1 week) 2 weeks 0.6 (0.5-0.9), 0.003 0.6 (0.4-0.9), 0.027 0.5 (0.3-0.8), 0.002 0.5 (0.3-0.8), 0.003 3 or more weeks 1.9 (1.1-3.4), 0.032 0.9 (0.4-2.2), 0.828 0.6 (0.2-1.9), 0.372 0.5 (0.1-1.9), 0.336 Asymptomatic 1.1 (0.
Aggarwal, Shrivastava, Kumar, Ali, Clinical and epidemiological features of SARS-CoV-2 patients in SARI ward of a tertiary care centre in New Delhi, J Assoc Physicians India
Albalawi, Alharbi, Bakouri, Alqahtani, Alanazi et al., Clinical characteristics and predictors of mortality among COVID-19 patients in Saudi Arabia, J Infect Public Health
Ards Definition, Force, Ranieri, Rubenfeld, Thompson et al., Acute respiratory distress syndrome: The Berlin Definition, JAMA
Bairwa, Kumar, Ajmal, Bahurupi, Kant, Predictors of critical illness and mortality based on symptoms and initial physical examination for patients with SARS-CoV-2: A retrospective cohort study, J Infect Public Health
Bellani, Laffey, Pham, Brochard, Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in Intensive Care Units in 50 countries, JAMA
Chauhan, Shadrach, Garg, Bhatia, Bhardwaj et al., Predictors of clinical outcomes in adult COVID-19 patients admitted to a tertiary care hospital in India: An analytical cross-sectional study, Acta Biomed
Gregoriano, Koch, Haubitz, Conen, Fux et al., Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: An observational analysis, Swiss Med Wkly
Gupta, Ish, Kumar, Dev, Yadav et al., Evaluation of the clinical profile, laboratory parameters and outcome of two hundred COVID-19 patients from a tertiary centre in India, Monaldi Archives for Chest Disease, doi:10.4081/monaldi.2020.1507
Mohan, Tiwari, Bhatnagar, Patel, Maurya et al., Clinico-demographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in North India, Indian J Med Res
Sagiraju, Elavarasi, Gupta, Garg, Paul et al., The effectiveness of SARS-CoV-2 vaccination in preventing severe illness and death-real-world data from a cohort of patients hospitalized with COVID-19, medRxiv, doi:10.1101/2021.08.26.21262705
Sirohiya, Elavarasi, Sagiraju, Baruah, Gupta et al., Silent hypoxia in coronavirus disease-2019: Is it more dangerous? -A retrospective cohort study, medRxiv, doi:10.1101/2021.08.26.21262668
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Zhang, Cao, Tan, Dong, Wang et al., Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients, Allergy
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop